Vanguard Group Inc. Lowers Holdings in CG Oncology, Inc. $CGON

Vanguard Group Inc. decreased its holdings in CG Oncology, Inc. (NASDAQ:CGON) by 0.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,539,482 shares of the company’s stock after selling 37,799 shares during the quarter. Vanguard Group Inc. owned approximately 0.08% of CG Oncology worth $271,519,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Whittier Trust Co. of Nevada Inc. purchased a new stake in CG Oncology in the 4th quarter valued at about $27,000. CWM LLC grew its holdings in shares of CG Oncology by 10.9% during the 3rd quarter. CWM LLC now owns 6,865 shares of the company’s stock worth $277,000 after purchasing an additional 672 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of CG Oncology by 33.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,920 shares of the company’s stock worth $163,000 after purchasing an additional 972 shares during the period. Strengthening Families & Communities LLC purchased a new stake in shares of CG Oncology during the 3rd quarter worth about $40,000. Finally, Swiss National Bank grew its holdings in shares of CG Oncology by 1.5% during the 3rd quarter. Swiss National Bank now owns 81,300 shares of the company’s stock worth $3,275,000 after purchasing an additional 1,200 shares during the period. Hedge funds and other institutional investors own 26.56% of the company’s stock.

Analyst Upgrades and Downgrades

CGON has been the subject of a number of research reports. Royal Bank Of Canada boosted their target price on CG Oncology from $73.00 to $79.00 and gave the stock an “outperform” rating in a report on Monday, April 27th. Morgan Stanley set a $93.00 target price on CG Oncology in a report on Friday, January 9th. JPMorgan Chase & Co. boosted their target price on CG Oncology from $65.00 to $91.00 and gave the stock an “overweight” rating in a report on Friday, April 17th. Wall Street Zen cut CG Oncology from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Finally, HC Wainwright boosted their target price on CG Oncology from $80.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, April 7th. Eleven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $79.55.

CG Oncology Stock Performance

CG Oncology stock opened at $69.62 on Friday. The stock’s 50 day moving average price is $65.66 and its 200 day moving average price is $52.87. The firm has a market capitalization of $6.13 billion, a PE ratio of -33.63 and a beta of 0.41. CG Oncology, Inc. has a one year low of $23.32 and a one year high of $73.56.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.12). The company had revenue of $1.08 million during the quarter, compared to analysts’ expectations of $0.45 million. On average, analysts forecast that CG Oncology, Inc. will post -2.56 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director James Mulay sold 15,600 shares of the business’s stock in a transaction that occurred on Friday, April 17th. The stock was sold at an average price of $73.01, for a total transaction of $1,138,956.00. Following the transaction, the director directly owned 15,600 shares of the company’s stock, valued at approximately $1,138,956. The trade was a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 4.80% of the company’s stock.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.